Companies: 10,795·Total market cap: $144.5T
Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc.

NRIXNASDAQHealthcare● Active
$15.54
+$0.90(+6.15%)
Market Cap$1.3B
P/E Ratio
52W High$22.5
52W Low$8.195
SEC Filings

Nurix Therapeutics, Inc. (NRIX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001549595 · NRIX · NASDAQ · as of Jun 8, 2026

Filing snapshot

515
Total Filings
8-K
Latest Form
2026-06-08
Most Recent
2020
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001549595 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-01-28
Fiscal Year End
Jan 28, 2026
Accession No.
0001549595-26-000016
Primary Document
nrix-20251130.htm
Source: data.sec.gov · CIK 0001549595 · Accession 0001549595-26-000016

Latest Key Filings

10-QQuarterly Report
10-Q
2026-04-08
8-KCurrent Report
8-K
2026-06-08Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-08
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
8-KCurrent Report
8-K
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-06
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-24
View
10-QQuarterly Report
10-Q
2026-04-08
View
8-KCurrent Report
8-K
2026-04-08
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-27
View
ARSARS
ARS
2026-03-27
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-03-27
View
DEF 14AProxy Statement
DEF 14A
2026-03-27
View
8-KCurrent Report
8-K
2026-03-06
View
424B5424B5
424B5
2026-03-06
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
Showing 1–15 of 254 filingsForm 4 / 144 hidden· 515 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001549595  |  Exchange: NASDAQ · Healthcare

Nurix Therapeutics, Inc. (NASDAQ: NRIX) has submitted 515 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001549595, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Nurix Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Nurix Therapeutics, Inc. 10-K was filed on 2026-01-28 for fiscal year ending 2026. Historical NRIX 10-K annual reports are available from 2012 through 2026.

Investors researching Nurix Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

NRIX SEC Filings · 8 questions

Nurix Therapeutics, Inc. (NRIX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 515 filings and access original documents at no cost. Nurix Therapeutics, Inc.'s CIK is 0001549595.

NRIX SEC filingsNurix Therapeutics, Inc. SEC documentsfind NRIX 10-K